Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Recs

1
Player Avatar KattyKay (82.90) Submitted: 10/6/2010 3:12:13 PM : Outperform Start Price: $4.50 CLDX Score: +180.17

Celldex Therapeutics, Inc. has strong science underlying it's drug candidates. The therapeutic use of a vaccine to 'teach' the immune system to control or remove the cancer cells is a unique niche that has few other candidate drugs. The clinical trial data is quite promising that this approach works in humans as well as in animals. Given the good clinical data so far, a new clinical development partner will be easier to find and negotiate with. This pick is a long-term pick though.

Featured Broker Partners


Advertisement